Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And investors become more bullish about its long-term prospects, and the potential the stock has to rise higher in value.
Vertex Pharmaceuticals (NASDAQ: VRTX) has many promising treatments in its pipeline, as it looks to build out its business beyond just the cystic fibrosis (CF) drugs that have enabled it to post strong profits and provide investors with stability. But it’s growing that portfolio of drugs which will lure in growth investors. And with a recent approval, the company can now add to its list of approved drugs.
On Jan. 30, the FDA granted approval for Vertex’s pain medication, Journavx. It’s a non-opioid treatment for moderate to severe acute pain. For the healthcare industry, this can be a valuable medication, as it gives patients an alternative to highly addictive opioids. In 2023, more than 81,000 people died from overdoses involving opioids, a number that was actually lower than the 84,000 who died the year before, according to data from the National Center for Health Statistics. It’s a serious problem in the U.S., and Journavx can play a key role in helping to bring these numbers down.
Analysts see huge potential for Journavx to become a blockbuster drug that could generate peak annual revenue of around $5 billion by 2031. For Vertex, this opens up an exciting new growth opportunity for the business, and it adds to an already strong portfolio of CF drugs.
Vertex has a solid business, but growth investors may be looking for much better numbers. The company recently released its latest earnings report, for the last quarter of 2024 as well as the entire year. In 2024, Vertex’s product revenue totaled $11 billion and rose by 12% year over year. This year, it’s projecting sales of around $12 billion as it expects “early contributions” from Journavx. As the company rolls out the new drug, that could help boost sales and lead to an acceleration of its growth in future years.
And Vertex still has more treatments in its pipeline, including medications aimed at treating type 1 diabetes, IgA nephropathy, APOL1-mediated kidney disease, and other conditions. Its growth rate may not look all that exciting today, but in the long run, the business has a lot of room to grow its sales and profits significantly.
Vertex’s double-digit growth rate is solid and its future remains bright, giving investors a lot of incentive to just hang on to the stock for the long term. Shares are also trading at 25 times its expected future earnings (based on analyst expectations), which isn’t a terribly high multiple given the company’s promising growth potential.
Year to date, shares of Vertex are up around 15%, and there could still be much more upside down the road. While the share price isn’t taking off just yet, as analysts raise their price targets based on its heightened growth potential and the company gets more attention, it may only be a matter of time before investors start to see the fantastic investment opportunity that the stock represents. Buying shares before that happens could be a great move to make today.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
-
Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $340,048!*
-
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,908!*
-
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $554,019!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of February 3, 2025
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing was originally published by The Motley Fool